Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Public ClinicalTrials.gov record NCT00983398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study of Intra-Arterial Melphalan Given With Intra-Arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Study identification
- NCT ID
- NCT00983398
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Enrollment
- 17 participants
Conditions and interventions
Conditions
- Central Nervous System Embryonal Neoplasm
- Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Germ Cell Tumor
- Medulloblastoma
- Medulloepithelioma
- Primitive Neuroectodermal Tumor
- Recurrent Childhood Central Nervous System Embryonal Neoplasm
- Recurrent Malignant Germ Cell Tumor
- Recurrent Medulloblastoma
- Recurrent Primitive Neuroectodermal Tumor
Interventions
- Carboplatin Drug
- Mannitol Drug
- Melphalan Drug
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
- Sodium Thiosulfate Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 8, 2009
- Primary completion
- Dec 30, 2021
- Completion
- Dec 30, 2022
- Last update posted
- Oct 25, 2021
2009 – 2022
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Minnesota/Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00983398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2021 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00983398 live on ClinicalTrials.gov.